Business Context and Reporting Period
This Form 8-K Current Report was filed by Aclaris Therapeutics, Inc. on April 25, 2018, covering events occurring on April 20, 2018. The filing primarily addresses corporate governance changes, specifically the appointment of a new director and audit committee chairman.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes
The material change reported is the appointment of Bryan Reasons to the Board of Directors and as Chairman of the Audit Committee, effective April 20, 2018. This appointment increased the Audit Committee membership from two to three members.
Management Commentary, Risks, and Unusual Items
Compensation Arrangements:
- Stock Options: Mr. Reasons was granted a nonqualified stock option to purchase 16,000 shares at an exercise price of $17.73 per share (closing price on the grant date). Vesting occurs in 36 equal monthly installments.
- Future Grants: Beginning with the 2019 annual meeting, he is entitled to an additional option for 8,000 shares annually, vesting over 12 months.
- Cash Retainers: He will receive a $35,000 annual retainer for director service and a $16,500 annual retainer for Audit Committee chairmanship.
Background: Mr. Reasons brings significant financial experience, having served as CFO of Impax Laboratories, Inc. since 2012, and previously held finance roles at Cephalon, Teva, DuPont, and PricewaterhouseCoopers.
Regulatory Disclosure: The company issued a press release on April 24, 2018, regarding this appointment, which is included as Exhibit 99.1 but is not deemed "filed" under the Exchange Act.
Investor Verification Checklist
- Verify the stock price of $17.73 on April 20, 2018, to confirm the exercise price of the granted options.
- Review the Company's 2015 Equity Incentive Plan to understand the specific vesting conditions and "Continuous Service" definitions.
- Confirm the total number of authorized shares and the impact of the 16,000 new options on potential dilution.
- Check subsequent filings to ensure Mr. Reasons' term was renewed at the 2018 annual meeting as scheduled.